Virnext and the academic laboratory VirPath announce the grant by the INPI of their patent in partnership with Signia Therapeutics for the repurposing of diltiazem as a modulator of the innate antiviral defence and its combination with current antivirals targeting SARS-CoV-2 variants.

Licensed to our spin-off Signia Therapeutics this patent expands the company’s portfolio and highlights the strength of the SIGNATURA® platform for drug identification and repurposing as innovative broad-spectrum host directed inhibitors of respiratory viruses influenza, pneumoviruses and SARS-CoV-2 variants. Our combinatorial strategy aims to potentiate antiviral therapy and mitigate the risk of spreading of already emerged and/or circulating resistance mutations to current virus-targeted antivirals.

For more information, see publications :

For more informations :

This work was supported by Université Claude Bernard Lyon 1 LYON INGENIERIE PROJETS EZUS LYON PULSALYS Région Auvergne-Rhône-Alpes @signia therapeutics Bpifrance #ilab NEOVACS INSERM Institut national de la santé et de la recherche médicale ANR (Agence nationale de la recherche) ANRT – Association Nationale de la Recherche et de la Technologie International Associated Laboratory RespiVir France – Canada